The Covid-19 vaccine, developed by AstraZeneca and the University of Oxford, protected people from new, more contagious coronavirus variants, at a level similar to the protection provided to other strains of the virus, Oxford said. Researchers said in a paper published on Friday.
The unreviewed paper stated that the vaccine was first detected in the United Kingdom and has a 74.6 percent efficacy against a new mutant known as B.1.1.7. This was similar, albeit slightly less effective than the virus against other strains.
Although preliminary, promising findings suggest that all five major vaccines may provide at least some protection against new variants of the virus that spread worldwide. Still, increasing evidence is that mutant viruses can reduce the effectiveness of vaccines, rapidly vaccinate their populations in countries, and increase pressure to outperform mutants that are established around the world. Suggests.
Oxford scientists behind the vaccine took weekly cotton swabs from the nose and throat of participants enrolled in a clinical trial in the United Kingdom. To determine the efficacy of the vaccine against the new variant, they removed the virus particles from hundreds of cotton swabs from October 1st to January 14th, when the new variant was known to exist in the United Kingdom. The sequence has been decided.
Vaccine efficacy was 84% against other strains of the virus and 74.6% against the new variant, but the small sample size produced a wide range of estimates.
Researchers also studied blood samples from vaccinated clinical trial participants and determined that the mutants may be more proficient in dodging the antibodies produced by the vaccine. did.
The first variants detected in the UK have since been reported in more than 70 countries. Public Health England estimates that the infection rate of this variant is 25% to 40% higher than other forms of coronavirus.
Preliminary data from laboratory tests of Pfizer and Moderna vaccines suggest that they provide excellent protection against the B.1.1.7 variant. Novavax, which sequenced test samples from clinical trial participants in the UK while the variant was widely distributed in the UK, found that the vaccine was highly effective against the B.1.1.7 variant. did.
The paper, published Friday, did not mention the protective power of the AstraZeneca vaccine against another rapidly spreading coronavirus variant known as B.1.351, which was first identified in South Africa. Researchers are conducting similar laboratory studies to measure the effect of the mutant on the efficacy of the vaccine.
The AstraZeneca vaccine is licensed in nearly 50 countries around the world, but not in the United States. In the United States, the Food and Drug Administration is waiting for data from clinical trials enrolling more than 30,000 participants (mainly Americans). The results of that study may be published this month, and AstraZeneca is expected to have sufficient safety data to seek an emergency permit from the FDA around the first week of March.
In the United States, B.1.1.7 variants have been identified in 33 states, but the full extent of their spread is unknown due to the lack of a national surveillance program. Federal health officials have warned that by March it could become a major form of the virus in the United States.
AstraZeneca Shot found to be protective against the first coronavirus mutant found in the United Kingdom
Source link AstraZeneca Shot found to be protective against the first coronavirus mutant found in the United Kingdom